Test Price
2,800 AED✅ Home Collection Available
ABCB11 Gene Sequencing for Benign Recurrent Intrahepatic Cholestasis Type 2 (BRIC2) in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
This NGS-based genetic test delivers over 99% diagnostic sensitivity for BRIC2, performed in an ISO 9001:2015 certified laboratory at DNA Labs UAE. Our premium service includes VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection (available daily from 8 AM to 11 PM), telephonic post-test clinical guidance, and direct insurance billing verification via WhatsApp at +971 54 548 8731. The full gene sequencing, interpreted by our Consultant Medical Geneticist Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), ensures accurate molecular diagnosis for recurrence risk assessment and personalized management.
Test Overview & Methodology
This test analyzes the entire coding sequence of the ABCB11 (BSEP) gene using Next Generation Sequencing (NGS) to identify pathogenic variants causing benign recurrent intrahepatic cholestasis type 2 (BRIC2). It is essential for confirming diagnosis in individuals with recurrent episodes of jaundice and pruritus, and for guiding family screening and surveillance.
| Feature | Our Test (NGS Full Gene Sequencing) | Closest Alternative (Targeted Mutation Panel) |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) covering all exons & splice sites | PCR-based screening for a limited set of known mutations |
| Diagnostic Yield | >95% detection of pathogenic variants in clinically suspected BRIC2 | ~60–70% as many rare mutations are missed |
| Turnaround Time | 3–4 Weeks | 2–4 Weeks |
| Interpretation | DHA-registered Consultant Medical Geneticist | Often automated or outsourced |
| Cost | 2,800 AED | 1,800–2,200 AED (incomplete analysis) |
Physician Insight & Safety Protocols
"ABCB11 full-gene sequencing is a precise molecular tool for confirming BRIC2 diagnosis. Identifying a pathogenic variant establishes the diagnosis with high confidence and allows for stratification of recurrence risk. It also opens the door for targeted family screening and informed reproductive planning. However, variant interpretation must always be correlated with the clinical phenotype, including cholestatic episode history and liver biochemistry." — Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403)
Clinical Advisory
Do not discontinue any prescribed medication, including ursodeoxycholic acid or rifampicin, without consulting your physician. Abrupt changes may trigger severe cholestatic flares. Maintain consistent follow-up with your hepatologist for liver function monitoring.
Exclusion Criteria & Emergency Red Flags
- This test is not intended for acute emergency diagnosis of acute liver failure or severe hyperbilirubinemia requiring immediate intervention.
- Not suitable as a stand-alone screening in asymptomatic individuals without a family history of cholestasis.
- If you experience severe jaundice with confusion, drowsiness, or bleeding, seek emergency care immediately.
- Avoid performing the test during an acute cholestatic episode without concurrent biochemical monitoring.
Patient FAQ & Clinical Guidance
1. What is the ABCB11 gene test and who should consider it?
This test sequences the ABCB11 gene to confirm benign recurrent intrahepatic cholestasis type 2 in individuals with episodic jaundice and itching. It is recommended for patients with unexplained recurrent cholestatic episodes, especially when triggered by pregnancy or oral contraceptives, and for family members of confirmed BRIC2 patients.
2. How is the test performed and what is the turnaround time?
A trained phlebotomist collects a blood sample in your home using a cold-chain transport kit, with results available in 3 to 4 weeks. Pre-test genetic counseling is mandatory to document family history and ensure informed consent.
3. What do positive or negative results mean for my health?
A positive result identifies the causative mutation, allowing precision management and family screening; a negative result may still require further evaluation if clinical suspicion remains high. In all cases, a specialist interpretation is provided during a post-test teleconsultation with our Consultant Medical Geneticist.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is securely encrypted and processed under the governance of the Dubai Health Authority (DHA). Clinical testing and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your privacy and data integrity are our commitment.
Clinical & Logistical Metadata
| Test Name | ABCB11 Gene Sequencing for Benign Recurrent Intrahepatic Cholestasis Type 2 (BRIC2) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Exon & Splice Site Analysis |
| ICD-10-CM Code | K83.1, Z13.228 |
| LOINC Code | 83900-7 |
| DHA Facility License & Laboratory Address | DNA Labs UAE | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians